We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+23.74%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$160M
AUM Growth
+$54.4M
Cap. Flow
+$34.5M
Cap. Flow %
21.53%
Top 10 Hldgs %
86.4%
Holding
49
New
32
Increased
5
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$7.86M
2
CRDF icon
Cardiff Oncology
CRDF
+$4.74M
3
SPRU icon
Spruce Power Holding Corp
SPRU
+$4.05M
4
SCYX icon
SCYNEXIS
SCYX
+$3.75M
5
ADXN
Addex Therapeutics
ADXN
+$3.08M

Top Sells

Rank Stock Value
1
GARS
Garrison Capital Inc.
GARS
+$4.45M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$1.88M
3
PSTH
Pershing Square Tontine Holdings, Ltd.
PSTH
+$1.53M
4
CCIV.U
Churchill Capital Corp IV Units, each consisting of one share of Class A common stock and one-fifth
CCIV.U
+$626K
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$370K

Sector Composition

Rank Sector Weight
1 Healthcare 80.99%
2 Technology 5.09%
3 Consumer Discretionary 2.25%
4 Financials 1.89%
5 Communication Services 1.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRDF icon
1
Cardiff Oncology
CRDF
$64.3M
$38M 23.72%
2,114,840
+269,676
+15% +$4.74M
MTEM
2
DELISTED
Molecular Templates, Inc.
MTEM
$19.9M 12.43%
141,533
– –
SBBP
3
DELISTED
Strongbridge Biopharma plc.
SBBP
$19.7M 12.25%
8,089,442
– –
CTIC
4
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$12.1M 7.53%
3,749,890
-563,727
-13% -$1.88M
SCYX icon
5
SCYNEXIS
SCYX
$37M
$11.3M 7.03%
184,296
+80,000
+77% +$3.75M
SRRA
6
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$10.3M 6.43%
643,959
– –
KALA icon
7
KALA BIO
KALA
$11.8M
$7.75M 4.83%
457
+148
+48% +$2.78M
GLD icon
8
SPDR Gold Trust
GLD
$131B
$7.34M 4.58%
41,161
+15,803
+62% +$2.78M
SPRU icon
9
Spruce Power Holding Corp
SPRU
$39.9M
$7.12M 4.44%
+37,500
New +$4.05M
RZLT icon
10
Rezolute
RZLT
$480M
$5.09M 3.17%
+424,243
New +$7.86M
ADXN
11
Addex Therapeutics
ADXN
$3.56M 2.22%
13,297
+12,427
+1,428% +$3.08M
CZOO
12
DELISTED
Cazoo Group Ltd
CZOO
$3.1M 1.93%
+125
New +$2.96M
LUXAU
13
DELISTED
Lux Health Tech Acquisition Corp. Units
LUXAU
$2.3M 1.43%
+200,000
New +$2.15M
MRACU
14
DELISTED
Marquee Raine Acquisition Corp. Unit
MRACU
$1.14M 0.71%
+105,500
New +$1.13M
BTWN
15
DELISTED
Bridgetown Holdings Limited Class A Ordinary Shares
BTWN
$1.13M 0.7%
+72,688
New +$977K
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$972K 0.61%
2,635
-1,127
-30% -$323K
HMCOU
17
DELISTED
HumanCo Acquisition Corp. Unit
HMCOU
$942K 0.59%
+85,500
New +$949K
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$933K 0.58%
134,981
-57,757
-30% -$370K
FLACU
19
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$664K 0.41%
+64,000
New +$668K
SCOAU
20
DELISTED
ScION Tech Growth I Unit
SCOAU
$604K 0.38%
+58,500
New +$603K
BCIC
21
BCP Investment Corp
BCIC
$86.9M
$571K 0.36%
+29,909
New +$451K
CDLX icon
22
Cardlytics
CDLX
$21M
$410K 0.26%
+287
New +$306K
DIS icon
23
Walt Disney
DIS
$165B
$339K 0.21%
+1,870
New +$268K
PYPL icon
24
PayPal
PYPL
$49.5B
$297K 0.19%
+1,267
New +$263K
TDG icon
25
TransDigm Group
TDG
$69.2B
$290K 0.18%
+469
New +$258K
1
2

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q4 2020 Portfolio in Review

As of Q4 2020, Caxton Corporation held 49 positions worth $160M, up 51% from $106M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Caxton Corporation deployed $34.5M of net new capital in Q4 2020, opening 32 new positions and adding to 5 existing holdings. Its largest new stake was Rezolute: 424,243 shares worth $5.09M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 89% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was CTI BioPharma Corp. (DE) Common Stock, an estimated $1.88M trimmed.

  • Caxton Corporation's largest Q4 2020 buy was Rezolute: 424,243 shares worth $5.09M.
  • Caxton Corporation added most to Cardiff Oncology in Q4 2020, an estimated $4.74M increase.
  • Caxton Corporation's biggest Q4 2020 reduction was CTI BioPharma Corp. (DE) Common Stock, cutting an estimated $1.88M.
  • Caxton Corporation fully exited Garrison Capital Inc. in Q4 2020, selling an estimated $4.45M.
  • Caxton Corporation's ten largest holdings make up 86% of its $160M portfolio in Q4 2020.
  • Caxton Corporation opened 32 new positions and closed 5 in Q4 2020.
  • Caxton Corporation's portfolio value rose 51% quarter-over-quarter to $160M.

Based on Caxton Corporation's 13F filing for Q4 2020, filed 16 Feb 2021.